03/23/2026
Are we overusing sugammadex… or finally using the right drug?
Sugammadex changed the game for neuromuscular reversal—rapid, predictable, and not dependent on acetylcholinesterase inhibition. But the real question in 2026 isn’t how it works… it’s when should you actually choose it over neostigmine?
⸻
Sugammadex vs Neostigmine — what actually matters clinically
Sugammadex
• Directly encapsulates rocuronium/vecuronium → true reversal
• Works in deep blockade (PTC 1–2)
• Faster, more reliable recovery
• Minimal hemodynamic effects
• Higher cost
Neostigmine
• Indirect reversal via acetylcholinesterase inhibition
• Requires partial recovery (TOF ≥2–4)
• Slower, less predictable
• Muscarinic side effects → requires glycopyrrolate
• Much lower cost
⸻
The Controversy
This is where anesthesia gets divided:
• Some argue sugammadex should be standard → improved safety, less residual paralysis, smoother emergence
• Others push back → cost vs benefit, especially in routine cases where neostigmine performs adequately
Key issue:
Are we preventing complications—or just buying convenience?
⸻
What the evidence suggests
• Sugammadex reduces residual neuromuscular blockade compared to neostigmine
• Faster extubation times and more predictable recovery
• But no consistent mortality benefit, and cost remains a major barrier
⸻
Clinical Bottom Line
Use sugammadex when it changes outcomes:
• Deep blockade
• High-risk airway or pulmonary patients
• Need for rapid, reliable reversal
Neostigmine still has a role:
• Routine cases
• Adequate spontaneous recovery already present
• Cost-sensitive environments
⸻
Reference:
Brull SJ, Kopman AF. Current Status of Neuromuscular Reversal and Monitoring. Anesthesiology. 2017;126(1):173–190.